Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the effects on disease activity, in the
absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly
by SC injection for 12 weeks.